Herceptin Proven To Benefit Women With HER2 Positive Early Breast Cancer Latest Results From The HERA Study

Study confirms Herceptin’s promise of extra years of living cancer free The Breast International Group (BIG) in collaboration with Roche announced that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for one year with Herceptin and followed up for four years.

More: continued here

Filed under: Breast Cancer on March 13th, 2009